Moreover, the somatic mutation landscape based on available WES data showed that subtype_II GBC samples altogether displayed TP53 mutation and high tumor mutational burden (TMB), which partly accounted for the activated immune signatures (Supplementary Fig. S7a)26. This evidence concerns the gene TP53 and neoplasm.